Prescriptions for insulin glargine-yfgn (Semglee) rapidly increased when its status switched from a standard biosimilar to ...

Glargine U300 use was common, especially with increased CKD stages and baseline HbA1c levels among patients with type 2 diabetes.

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

Brazil's Minister of Health, Alexandre Padilha and his delegation visited Gan & Lee Pharmaceuticals' headquarters on May 12, ...

Lilly and Boehringer Ingelheim have gained EU approval for their biosimilar version of Sanofi's blockbuster insulin product Lantus (insulin glargine). The Europe-wide approval is the first ever ...

Inclusion of basal insulin glargine in multiple daily injection (MDI) regimens decreases glycemic variability in adolescents with type 1 diabetes mellitus (T1DM), according to US researchers.

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Discover the commercial and brand names of the generic drug Insulin Glargine. This indispensable guide is essential for healthcare professionals, patients, caregivers, and anyone seeking to ...

The aim of this study was - in routine clinical settings in Denmark - to compare daily doses of DET and GLAR in T2D patients when administered once daily.